192 related articles for article (PubMed ID: 33095670)
41. A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer.
Lock M; Best L; Wong E; Bauman G; D'Souza D; Venkatesan V; Sexton T; Ahmad B; Izawa J; Rodrigues G
Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1306-15. PubMed ID: 20708855
[TBL] [Abstract][Full Text] [Related]
42. Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial.
Leite ETT; Ramos CCA; Ribeiro VAB; Salvajoli BP; Nahas WC; Salvajoli JV; Ynoe Moraes F
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1263-1270. PubMed ID: 33346091
[TBL] [Abstract][Full Text] [Related]
43. A pilot study of stereotactic body radiotherapy combined with pelvic radiotherapy and GTVp boost based on multiparameter magnetic resonance image in patients with high-risk prostate cancer.
Wang F; Yao J; Chen J; Zeng H; Wang X
Medicine (Baltimore); 2023 Sep; 102(39):e35260. PubMed ID: 37773877
[TBL] [Abstract][Full Text] [Related]
44. Dose-escalation of five-fraction SABR in prostate cancer: Toxicity comparison of two prospective trials.
Musunuru HB; Quon H; Davidson M; Cheung P; Zhang L; D'Alimonte L; Deabreu A; Mamedov A; Loblaw A
Radiother Oncol; 2016 Jan; 118(1):112-7. PubMed ID: 26796591
[TBL] [Abstract][Full Text] [Related]
45. Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints.
Meier RM; Bloch DA; Cotrutz C; Beckman AC; Henning GT; Woodhouse SA; Williamson SK; Mohideen N; Dombrowski JJ; Hong RL; Brachman DG; Linson PW; Kaplan ID
Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):296-303. PubMed ID: 30191864
[TBL] [Abstract][Full Text] [Related]
46. Stereotactic Body Radiation Therapy for the Curative Treatment of Prostate Cancer in Ultralarge (≥100 cc) Glands.
Hurwitz JC; Haas J; Mendez C; Sanchez A; Santos VF; Akerman M; Carpenter T; Tam M; Katz A; Corcoran A; Mahadevan A; Taneja SS; Lepor H; Lischalk JW
Pract Radiat Oncol; 2024; 14(3):241-251. PubMed ID: 37984713
[TBL] [Abstract][Full Text] [Related]
47. 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment.
Alongi F; Rigo M; Figlia V; Cuccia F; Giaj-Levra N; Nicosia L; Ricchetti F; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Mazzola R
Radiat Oncol; 2020 Mar; 15(1):69. PubMed ID: 32248826
[TBL] [Abstract][Full Text] [Related]
48. "Give me five" ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach.
Marvaso G; Riva G; Ciardo D; Gandini S; Fodor C; Zerini D; Colangione SP; Timon G; Comi S; Cambria R; Cattani F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Med Oncol; 2018 May; 35(6):96. PubMed ID: 29748830
[TBL] [Abstract][Full Text] [Related]
49. From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: Primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial.
De Cock L; Draulans C; Pos FJ; Isebaert S; De Roover R; van der Heide UA; Smeenk RJ; Kunze-Busch M; van der Voort van Zyp J; de Boer H; Kerkmeijer LGW; Haustermans K
Radiother Oncol; 2023 Aug; 185():109713. PubMed ID: 37178932
[TBL] [Abstract][Full Text] [Related]
50. Acute side effects after definitive stereotactic body radiation therapy (SBRT) for patients with clinically localized or locally advanced prostate cancer: a single institution prospective study.
Jorgo K; Polgar C; Stelczer G; Major T; Gesztesi L; Agoston P
Radiol Oncol; 2021 Jul; 55(4):474-481. PubMed ID: 34253001
[TBL] [Abstract][Full Text] [Related]
51. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes.
Cahlon O; Zelefsky MJ; Shippy A; Chan H; Fuks Z; Yamada Y; Hunt M; Greenstein S; Amols H
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):330-7. PubMed ID: 18164858
[TBL] [Abstract][Full Text] [Related]
52. A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer.
Kawakami S; Tsumura H; Satoh T; Tabata K; Sekiguchi A; Kainuma T; Nakano M; Iwamura M; Ishiyama H
Radiat Oncol; 2022 Apr; 17(1):67. PubMed ID: 35379264
[TBL] [Abstract][Full Text] [Related]
53. Early Results of Extreme Hypofractionation Using Stereotactic Body Radiation Therapy for High-risk, Very High-risk and Node-positive Prostate Cancer.
Murthy V; Gupta M; Mulye G; Maulik S; Munshi M; Krishnatry R; Phurailatpam R; Mhatre R; Prakash G; Bakshi G
Clin Oncol (R Coll Radiol); 2018 Jul; 30(7):442-447. PubMed ID: 29571936
[TBL] [Abstract][Full Text] [Related]
54. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.
Fuller DB; Wurzer J; Shirazi R; Bridge SS; Law J; Mardirossian G
Pract Radiat Oncol; 2015; 5(6):e615-23. PubMed ID: 26059509
[TBL] [Abstract][Full Text] [Related]
55. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.
Chen LN; Suy S; Uhm S; Oermann EK; Ju AW; Chen V; Hanscom HN; Laing S; Kim JS; Lei S; Batipps GP; Kowalczyk K; Bandi G; Pahira J; McGeagh KG; Collins BT; Krishnan P; Dawson NA; Taylor KL; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2013 Mar; 8():58. PubMed ID: 23497695
[TBL] [Abstract][Full Text] [Related]
56. Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer.
Boyer MJ; Papagikos MA; Kiteley R; Vujaskovic Z; Wu J; Lee WR
Radiat Oncol; 2017 Jan; 12(1):14. PubMed ID: 28086825
[TBL] [Abstract][Full Text] [Related]
57. Dosimetric Predictors of Toxicity after Prostate Stereotactic Body Radiotherapy: A Single-Institutional Experience of 145 Patients.
Fujii K; Nakano M; Kawakami S; Tanaka Y; Kainuma T; Tsumura H; Tabata KI; Satoh T; Iwamura M; Ishiyama H
Curr Oncol; 2023 May; 30(5):5062-5071. PubMed ID: 37232841
[TBL] [Abstract][Full Text] [Related]
58. 11C choline PET guided salvage radiotherapy with volumetric modulation arc therapy and hypofractionation for recurrent prostate cancer after HIFU failure: preliminary results of tolerability and acute toxicity.
Alongi F; Liardo RL; Iftode C; Lopci E; Villa E; Comito T; Tozzi A; Navarria P; Ascolese AM; Mancosu P; Tomatis S; Bellorofonte C; Arturo C; Scorsetti M
Technol Cancer Res Treat; 2014 Oct; 13(5):395-401. PubMed ID: 24000995
[TBL] [Abstract][Full Text] [Related]
59. Stereotactic body radiotherapy as boost for organ-confined prostate cancer.
Katz AJ; Santoro M; Ashley R; Diblasio F; Witten M
Technol Cancer Res Treat; 2010 Dec; 9(6):575-82. PubMed ID: 21070079
[TBL] [Abstract][Full Text] [Related]
60. 50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
Herrera FG; Valerio M; Berthold D; Tawadros T; Meuwly JY; Vallet V; Baumgartner P; Thierry AC; De Bari B; Jichlinski P; Kandalaft L; Coukos G; Harari A; Bourhis J
Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):320-334. PubMed ID: 30267761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
